Journal
EJHaem
Publication Date
5-1-2023
Volume
4
Issue
2
First Page
370
Last Page
380
Document Type
Open Access Publication
DOI
10.1002/jha2.687
Rights and Permissions
Narkhede M, Bartlett NL, Ibrahimi S, Popplewell L, Seto A, Bates J, et al. A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). eJHaem. 2023; 4: 370–380. https://doi.org/10.1002/jha2.687 © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Narkhede, Mayur; Bartlett, Nancy L; Ibrahimi, Sami; Popplewell, Leslie; Seto, Anna; Bates, Jamie; Lee, Yeonju; Ganti, Vaishnavi; Han, Ling; Chen, Tianling; and Patel, Manish R, "A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)." EJHaem. 4, 2. 370 - 380. (2023).
https://digitalcommons.wustl.edu/oa_4/2835
Additional Links
Supplemental material is available for this article at publisher site.
